Sirona Biochem (TSXV:SBM) Cash-to-Debt : 0.05 (As of Jan. 2024)

View and export this data going back to 2007. Start your Free Trial

What is Sirona Biochem Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Sirona Biochem's cash to debt ratio for the quarter that ended in Jan. 2024 was 0.05.

If Cash to Debt ratio is less than 1, the company cannot pay off its debt using the cash in hand. Here we can see, Sirona Biochem couldn't pay off its debt using the cash in hand for the quarter that ended in Jan. 2024.

The historical rank and industry rank for Sirona Biochem's Cash-to-Debt or its related term are showing as below:

TSXV:SBM' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.02 Med: 0.62 Max: 2.49
Current: 0.05

During the past 13 years, Sirona Biochem's highest Cash to Debt Ratio was 2.49. The lowest was 0.02. And the median was 0.62.

TSXV:SBM's Cash-to-Debt is ranked worse than
96.3% of 1539 companies
in the Biotechnology industry
Industry Median: 6.49 vs TSXV:SBM: 0.05

Sirona Biochem Cash-to-Debt Historical Data

The historical data trend for Sirona Biochem's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Sirona Biochem Cash-to-Debt Chart

Sirona Biochem Annual Data

Trend

Oct14

Oct15

Oct16

Oct17

Oct18

Oct19

Oct20

Oct21

Oct22

Oct23

Cash-to-Debt

Get a 7-Day Free Trial

2.41

1.24

0.91

0.90

0.26

Sirona Biochem Quarterly Data
	Apr19	Jul19	Oct19	Jan20	Apr20	Jul20	Oct20	Jan21	Apr21	Jul21	Oct21	Jan22	Apr22	Jul22	Oct22	Jan23	Apr23	Jul23	Oct23	Jan24
Cash-to-Debt	Get a 7-Day Free Trial															0.35	0.58	0.19	0.26	0.05

Competitive Comparison of Sirona Biochem's Cash-to-Debt

For the Biotechnology subindustry, Sirona Biochem's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Sirona Biochem's Cash-to-Debt Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Sirona Biochem's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Sirona Biochem's Cash-to-Debt falls into.

Sirona Biochem Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Sirona Biochem's Cash to Debt Ratio for the fiscal year that ended in Oct. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	0.571	/	(0.644	+	1.539)
	=	0.26

Sirona Biochem's Cash to Debt Ratio for the quarter that ended in Jan. 2024 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	0.112	/	(0.791	+	1.556)
	=	0.05

Sirona Biochem (TSXV:SBM) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Sirona Biochem Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Sirona Biochem's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Sirona Biochem (TSXV:SBM) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sirona Biochem Corp (TSXV:SBM) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

SRBCF:USA ZSB:Germany

Address

C/o WeWork, 595 Burrard Street, Vancouver, BC, CAN, V7X 1L3

Website

https://www.sironabiochem.com

Sirona Biochem Corp is a development stage biotechnology company. The principal activities of the company are the development of cosmetic and pharmaceutical active ingredients which are licensed to partners in exchange for upfront, milestone, and royalty payments. The company acts as a cosmetic ingredient and drug discovery company with a proprietary technology platform with a specialization in the stabilization of carbohydrate molecules. It has a business presence in Canada and France.